Case Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine

Simple item page
dc.contributor.authorJaime Alberto Restrepo Soto
dc.contributor.authorMaría Isabel Méndez
dc.contributor.authorJonathan Berman
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T16:35:41Z
dc.date.available2026-03-22T16:35:41Z
dc.date.issued2021
dc.descriptionCitaciones: 1
dc.description.abstractWe present case reports of two patients treated with miltefosine for mucocutaneous leishmaniasis whose gastrointestinal symptoms were initially diagnosed as a drug reaction and only later recognized as due to COVID-19. Gastrointestinal symptoms of COVID-19 are unusual, whereas gastrointestinal adverse drug reactions are very common. These reports exemplify that this infrequent presentation of COVID-19 is likely to be ascribed to a more common etiology such as a gastrointestinal drug reaction.
dc.identifier.doi10.4269/ajtmh.20-1510
dc.identifier.urihttps://doi.org/10.4269/ajtmh.20-1510
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/59164
dc.language.isoen
dc.publisherAmerican Society of Tropical Medicine and Hygiene
dc.relation.ispartofAmerican Journal of Tropical Medicine and Hygiene
dc.sourceCentro Nacional de Enfermedades Tropicales
dc.subjectMiltefosine
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subject2019-20 coronavirus outbreak
dc.subjectMedicine
dc.subjectDrug
dc.subjectBetacoronavirus
dc.subjectVirology
dc.subjectPharmacology
dc.titleCase Report: COVID-19 Misdiagnosed as a Drug Reaction to Miltefosine
dc.typearticle

Files

Collections

Artículo Científico Publicado